Please Note: THIS FORUM IS PATIENT MODERATED AND IS NOT CONNECTED TO ANY CLINIC OR DOCTOR. IF YOU WISH TO CONTACT A CERTAIN DOCTOR OR CLINIC, PLEASE LOOK IN THE ASK THE DOCTOR SECTION FOR DOCTOR OR CLINIC PHONE NUMBERS AND EMAIL ADDRESSES.

                        Home || Contact Us || Help Registering and Participating || Disclaimer


 SeaChange now offers CBD Oil

 

Barbara and Jeannine's Book

Bea Luis Memorial

 


Results 1 to 2 of 2

Thread: Israeli Startup Nano Dimension 3D Prints Human Stem Cells

  1. #1
    Join Date
    Jan 2008
    Location
    Riverside, CA
    Posts
    359

    Default Israeli Startup Nano Dimension 3D Prints Human Stem Cells

    From: <http://nocamels.com/2016/06/nano-dimension-3d-prints-human-stem-cells/?utm_source=activetrail&utm_medium=email&utm_campa ign=nc9/06/16>

    Using plastics, nylon and metals to 3D print objects has already transformed the way companies around the world manufacture their prototypes and products. But the printing of stem cells – multicellular organisms capable of giving rise to more cells of the same type – provides for a much more serious application of the technology, one that could save many lives.

    Israeli company Nano Dimension has successfully lab-tested a 3D bioprinter for stem cells, making it very possible that human tissue and organs can be manufactured using 3D printing in the not too distant future. 3D bioprinting is the process of creating cell patterns in a confined space using 3D printing technologies, where cell function and viability are preserved, creating tissue-like structures that are later used in the medical and tissue engineering fields.

    In order to develop these high-quality cells, Nano Dimension turned to another Israeli startup, Haifa-based Accellta, to collaborate on the trial. The feasibility study confirmed that the combined know-how and technologies of the companies enabled printing of viable stem cells using an adapted 3D printer.

    According to Nano Dimension CEO Amit Dror, “3D printing of living cells is a technology that is already playing a significant role in medical research, but in order to reach its full potential, for the field to evolve further, there is a need to improve printing speeds, print resolution, cell control and viability as well as cell availability and bio-ink technologies. By combining our high-speed, high-precision inkjet capabilities with Accellta’s stem cell suspension technologies and induced differentiation capabilities led by a world-renown group of experienced engineers and scientists, we can enable 3D printing at high resolution and high volumes.”

    The companies will consider the formation of a new venture for these future solutions, and do not intend to invest significant capital directly to expand this activity. Such funds would be raised by and for the use of the joint venture.

    3D bioprinting enabled by the two companies’ technologies, means that Nano Dimension and Accellta have the potential to accelerate high-fidelity and high-viability manufacturing of living cellular products. Accellta’s unique, robust and reproducible suspension-based cell culturing systems produce billions of high-quality stem cells per batch and represent a transformative step in terms of stem cell production. Accellta’s technology can deliver large quantities of high-quality cells, which can be an enabler for printing even larger and more complex tissues – even whole organs in the future.

  2. #2
    Join Date
    May 2007
    Posts
    13,359
    Blog Entries
    5

    Default 3D Nanoprinting seems to be the talk of the industry

    Initiative Underway to Replicate Brain’s Neural Networks Through 3D Nanoprinting
    06/09/2016 by Axol Bioscience

    The MESO-BRAIN initiative, a project targeting a transformative progress in photonics, neuroscience and medicine has received €3.3 million ($3.7 million) in funding from the European Commission through its Future and Emerging Technology program (part of Horizon 2020).

    The project aims to develop three-dimensional human neural networks with specific biological architecture, and the inherent ability to interrogate the network’s brain-like activity both electrophysiologically and optically.

    It is expected that the MESO-BRAIN will facilitate a better understanding of human disease progression, neuronal growth and enable the development of large-scale human cell-based assays to test the modulatory effects of pharmacological and toxicological compounds on neural network activity. The use of more physiologically relevant human models will increase drug screening efficiency and reduce the need for animal testing.

    The project’s cornerstone will use human induced pluripotent stem cells (iPSCs) that have been differentiated into neurons upon a defined and reproducible 3D scaffold to support the development of human neural networks that emulate brain activity.

    The structure will be based on a brain cortical module and will be unique in that it will be designed and produced using nanoscale 3D-laser-printed structures incorporating nano-electrodes to enable downstream electrophysiological analysis of neural network function.

    Optical analysis will be conducted using light sheet-based, fast volumetric imaging technology to enable cellular resolution throughout the 3D network. The MESO-BRAIN project will allow for a comprehensive and detailed investigation of neural network development in health and disease.

    “What we’re proposing to achieve with this project has, until recently, been the stuff of science fiction," Edik Rafailov, head of the project at Aston University, said in a statement. "Being able to extract and replicate neural networks from the brain through 3D nanoprinting promises to change this. The MESO-BRAIN project has the potential to revolutionise the way we are able to understand the onset and development of disease and discover treatments for those with dementia or brain injuries."

    The project will launch in September and research will be conducted over three years.

    Each of the consortium partners have been chosen on the basis of their specific skills and knowledge, including technologies and expertise in stem cells, photonics, physics, 3D nanoprinting, electrophysiology, molecular biology, imaging and commercialization.

    The partners are: Aston University (U.K.); Axol Bioscience Ltd. (U.K.); Laser Zentrum Hannover (Germany); University of Barcelona (Spain); Institute of Photonic Sciences (Spain), and KITE Innovation (U.K.).
    First treatment in 2007. Pioneering ever since.

    Barbara

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  

Copyright 2007 - 2011 Stem Cell Pioneers